Nilvadipine
From Wikipedia, the free encyclopedia
 |
|
|
Nilvadipine
|
|
| Systematic (IUPAC) name | |
| O3-Methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | |
| Identifiers | |
| CAS number | ? |
| ATC code | C08 |
| PubChem | |
| Chemical data | |
| Formula | C19H19N3O6 |
| Mol. mass | 385.370 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension and chronic major cerebral artery occlusion.
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.
Currently, nilvadipine is tested in clinical trial as a possible treatment for Alzheimer's Disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland. [1]
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
